Valneva announces success of its private placement, raising approximately €60 million

Saint-Herblain (France), September 13, 2024 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) (“Valneva” or the “Company”), a specialty vaccine company, today announces the successful pricing of its Private Placement (as defined below) for a final amount of €61,180,000.

Peter Bühler, CFO of Valnevanoted: “We would like to thank our existing shareholders for their continued support, as well as the new healthcare specialist investors who are joining us through this capital increase. In addition to supporting our current commercial and R&D activities, this additional capital will give us greater flexibility to invest in our future growth, including in the Shigella vaccine program for which we recently acquired an exclusive global license.”